Literature DB >> 12190286

The pathology of inherited breast cancer.

Jane E Armes1, Deon J Venter.   

Abstract

Familial breast cancer has been recognised for many years. In the 1990s the genetic mechanism of inheritance of a proportion of these familial cancers was found to be attributable to germline mutation in either of two newly discovered genes, namely BRCA1 and BRCA2. Since the discovery of these genes, studies have been performed in which the pathological characteristics of familial cancers arising in patients with germline BRCA1 and BRCA2 mutation have been examined. A distinct pathological phenotype of high-grade, oestrogen receptor-negative breast cancer, often with medullary features, has been consistently described for BRCA1 cancers. A less distinct phenotype has been described for BRCA2 cancers. The discovery of genotype-phenotype correlation has significant implications for patient management and novel treatment strategies, not only for inherited cancers, but for breast cancer in general.

Entities:  

Mesh:

Year:  2002        PMID: 12190286     DOI: 10.1080/00313020220147113

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  16 in total

1.  Is no news good news? Inconclusive genetic test results in BRCA1 and BRCA2 from patients and professionals' perspectives.

Authors:  Audrey Ardern-Jones; Regina Kenen; Elly Lynch; Rebecca Doherty; Rosalind Eeles
Journal:  Hered Cancer Clin Pract       Date:  2010-01-12       Impact factor: 2.857

2.  Prediction of BRCA1 germline mutation status in women with ovarian cancer using morphology-based criteria: identification of a BRCA1 ovarian cancer phenotype.

Authors:  Mika Fujiwara; Valerie A McGuire; Anna Felberg; Weiva Sieh; Alice S Whittemore; Teri A Longacre
Journal:  Am J Surg Pathol       Date:  2012-08       Impact factor: 6.394

Review 3.  The contribution of breast cancer pathology to statistical models to predict mutation risk in BRCA carriers.

Authors:  Ana Cristina Vargas; Leonard Da Silva; Sunil R Lakhani
Journal:  Fam Cancer       Date:  2010-12       Impact factor: 2.375

Review 4.  How many etiological subtypes of breast cancer: two, three, four, or more?

Authors:  William F Anderson; Philip S Rosenberg; Aleix Prat; Charles M Perou; Mark E Sherman
Journal:  J Natl Cancer Inst       Date:  2014-08-12       Impact factor: 13.506

5.  Ownership of uncertainty: healthcare professionals counseling and treating women from hereditary breast and ovarian cancer families who receive an inconclusive BRCA1/2 genetic test result.

Authors:  Regina Kenen; Audrey Ardern-Jones; Elly Lynch; Rosalind Eeles
Journal:  Genet Test Mol Biomarkers       Date:  2011-01-22

6.  Distinction between hereditary and sporadic breast cancer on the basis of clinicopathological data.

Authors:  P van der Groep; A Bouter; R van der Zanden; I Siccama; F H Menko; J J P Gille; C van Kalken; E van der Wall; R H M Verheijen; P J van Diest
Journal:  J Clin Pathol       Date:  2006-04-07       Impact factor: 3.411

7.  Histologic features of melanoma associated with CDKN2A genotype.

Authors:  Michael R Sargen; Peter A Kanetsky; Julia Newton-Bishop; Nicholas K Hayward; Graham J Mann; Nelleke A Gruis; Margaret A Tucker; Alisa M Goldstein; Giovanna Bianchi-Scarra; Susana Puig; David E Elder
Journal:  J Am Acad Dermatol       Date:  2015-01-13       Impact factor: 11.527

8.  Distress and psychosocial needs of a heterogeneous high risk familial cancer population.

Authors:  Tara E Power; John W Robinson; Peter Bridge; Francois P Bernier; Dawna M Gilchrist
Journal:  J Genet Couns       Date:  2011-04-21       Impact factor: 2.537

Review 9.  Phenotype-genotype correlation in familial breast cancer.

Authors:  Ana Cristina Vargas; Jorge S Reis-Filho; Sunil R Lakhani
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-03-12       Impact factor: 2.673

10.  Rare breast neoplasms: is there any peculiar feature on magnetic resonance mammography?

Authors:  A Linda; V Londero; F Mazzarella; C Zuiani; M Bazzocchi
Journal:  Radiol Med       Date:  2007-09-20       Impact factor: 3.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.